U.S. Stem Cell, Inc. (USRM)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
+0.0001 (0.00%)
At close: Dec 31, 2024
U.S. Stem Cell Revenue
In the year 2022, U.S. Stem Cell had annual revenue of $82.05K, down -59.13%. U.S. Stem Cell had revenue of $19.97K in the quarter ending December 31, 2022, a decrease of -15.34%.
Revenue
82.05K
Revenue Growth
-59.13%
P/S Ratio
0.01
Revenue / Employee
7.46K
Employees
11
Market Cap
662.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 82.05K | -118.70K | -59.13% |
| Dec 31, 2021 | 200.75K | -76.34K | -27.55% |
| Dec 31, 2020 | 277.09K | -2.80M | -90.98% |
| Dec 31, 2019 | 3.07M | -3.63M | -54.15% |
| Dec 31, 2018 | 6.70M | 1.18M | 21.38% |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2013 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
U.S. Stem Cell News
- 3 years ago - Mark Borman Appointed Chairman of the Board of USRM - Accesswire